Stockscreener 앱 받기
23.99
1.28%
-0.31
Dyne Therapeutics Inc 주식(DYN)의 최신 뉴스
Barclays PLC Purchases 128,246 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Wellington Management Group LLP Reduces Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Franklin Resources Inc. Cuts Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
State Street Corp Raises Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Shares Gap UpWhat's Next? - MarketBeat
Dyne Therapeutics initiated with Outperform at Baird - MSN
Dyne Therapeutics (NASDAQ:DYN) Upgraded at Raymond James - MarketBeat
How to Take Advantage of moves in (DYN) - Stock Traders Daily
Baird Initiates Coverage of Dyne Therapeutics (DYN) with Outperform Recommendation - MSN
Dyne Therapeutics (NASDAQ:DYN) Now Covered by Robert W. Baird - MarketBeat
29,694 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Acquired by Y Intercept Hong Kong Ltd - MarketBeat
DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm! - The Eastern Progress Online
Baird sets $46 target on Dyne Therapeutics, sees upside By Investing.com - Investing.com UK
Dyne therapeutics SVP Richard Scalzo sells $40,914 in stock By Investing.com - Investing.com Nigeria
Dyne therapeutics SVP Richard Scalzo sells $40,914 in stock - Investing.com India
Dyne therapeutics' chief scientific officer sells $65,632 in stock By Investing.com - Investing.com UK
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - The Eastern Progress Online
Point72 Asset Management L.P. Sells 255,038 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
The Manufacturers Life Insurance Company Sells 20,029 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics, Inc. (NASDAQ:DYN) Position Boosted by Charles Schwab Investment Management Inc. - MarketBeat
Dyne Therapeutics (DYN) Stock Drops Amidst Biotech Sector Moveme - GuruFocus.com
Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock Holdings Boosted by RTW Investments LP - MarketBeat
RA Capital Management L.P. Grows Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $50.82 Consensus Target Price from Analysts - MarketBeat
Janus Henderson Group PLC Raises Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
HighVista Strategies LLC Makes New $2.35 Million Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Holocene Advisors LP Sells 93,712 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Piper Sandler maintains $53 target on Dyne Therapeutics stock By Investing.com - Investing.com Canada
Fmr LLC Has $324.24 Million Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Shares Down 4.2%Time to Sell? - MarketBeat
Eventide Asset Management LLC Sells 152,723 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Intech Investment Management LLC Purchases New Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Myotonic dystrophy pipeline shows momentum - The Pharma Letter
Acuta Capital Partners LLC Sells 166,300 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Myotonic Dystrophy Clinical Trial Pipeline Boom as Over 20 Companies Leading the Charge in Research and Development | DelveInsight - The Malaysian Reserve
Connor Clark & Lunn Investment Management Ltd. Invests $1.48 Million in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Victory Capital Management Inc. Purchases 11,385 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne, Avidity initiated at outperform by RBC on DM1 drugs (NASDAQ:DYN) - Seeking Alpha
Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated at Royal Bank of Canada - MarketBeat
RBC Capital starts Dyne Therapeutics shares at Outperform, targets genetic medicine success - Investing.com UK
Principal Financial Group Inc. Reduces Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Susanna High named CEO of Paragon - BioCentury
Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey
Jennison Associates LLC Has $48.38 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
DYN (Dyne Therapeutics) 9-Day RSI : 49.47 (As of Nov. 21, 2024) - GuruFocus.com
Dyne Therapeutics director Incerti Carlo sells $474,045 in stock - Investing.com India
2.88%
2.65%
자본화:
|
볼륨(24시간):